Marshall Wace, LLP
- SEC CIK
- 0001318757
- Latest filing
- Aug 13, 2026
ARWR holding history
Arrowhead Pharmaceuticals, Inc. in every 13F filed by Marshall Wace, LLP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ARWR overviewAll 13F holders of ARWRFull Q2 2026 holdings
- Shares (Q2 2026)
- 305,031
- Value
- $24.9M
- % of portfolio
- <0.1%
- Quarters held
- 11
- Since Q2 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 305,031 | $24.9M | <0.1% | +125,458+69.9% | Added | Holders |
| Q1 2026 | 179,573 | $11.3M | <0.1% | +55,718+45.0% | Added | Holders |
| Q4 2025 | 123,855 | $8.22M | <0.1% | −1,312,985−91.4% | Reduced | Holders |
| Q3 2025 | 1,436,840 | $49.6M | 0.1% | −719,158−33.4% | Reduced | Holders |
| Q2 2025 | 2,155,998 | $34.1M | <0.1% | +2,096,238+3,507.8% | Added | Holders |
| Q1 2025 | 59,760 | $761.3K | <0.1% | −26,873−31.0% | Reduced | Holders |
| Q4 2024 | 86,633 | $1.63M | <0.1% | +86,633 | New | Holders |
| Q4 2023 | 0 | $0 | 0.0% | −107,648−100.0% | Sold out | Holders |
| Q3 2023 | 107,648 | $2.89M | <0.1% | −193,393−64.2% | Reduced | Holders |
| Q2 2023 | 301,041 | $10.7M | <0.1% | +301,041 | New | Holders |
| Q2 2022 | 0 | $0 | 0.0% | −182,799−100.0% | Sold out | Holders |
| Q1 2022 | 182,799 | $8.41M | <0.1% | +182,799 | New | Holders |
| Q3 2021 | 0 | $0 | 0.0% | −250,380−100.0% | Sold out | Holders |
| Q2 2021 | 250,380 | $20.7M | 0.1% | +250,380 | New | Holders |